SCHEMBL6209850

SCHEMBL6209850

Cn1ncc2cc(Oc3ccc(N)cn3)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
POLB P06746 2/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 1/20 0.51
BRCA1 P38398 1/20 0.51
HBB P68871 1/20 0.51
HSD17B10 Q99714 1/20 0.51
RAB9A P51151 1/20 0.49
CDC7 O00311 1/20 0.41
KEAP1 Q14145 1/20 0.39
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
DAPK3 O43293 1/20 0.37
CSNK1A1 P48729 1/20 0.37
GSK3A P49840 1/20 0.37
LIMK1 P53667 1/20 0.37
IKBKE Q14164 1/20 0.37
MAPK14 Q16539 1/20 0.37
TAOK1 Q7L7X3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6211088 0.80 HSPB1 (0.55) MEN1KMT2AALDH1A1RAB9A
SCHEMBL3709809 0.79 KDM4E (0.50) KDM4EPOLBMEN1KMT2AALDH1A1
SCHEMBL6210172 0.78 KDM4E (0.59) KDM4EPOLBMEN1KMT2A
SCHEMBL6209189 0.76 CYP11B2 (0.53) KDM4EPOLBMEN1KMT2AALDH1A1
SCHEMBL378619 0.76 CHEK1 (0.57) CDC7CHEK1AURKADAPK3CSNK1A1
SCHEMBL30006507 0.76 CHEK1 (0.57) CDC7CHEK1AURKADAPK3CSNK1A1
SCHEMBL6210535 0.75 PGR (0.50) KDM4EPOLBMEN1KMT2AALDH1A1
SCHEMBL5343977 0.74 CHEK1 (0.56) CDC7CHEK1AURKADAPK3CSNK1A1
SCHEMBL15332949 0.73 TRPA1 (0.46) CDC7CHEK1AURKADAPK3CSNK1A1
SCHEMBL2448658 0.73 CYP11B1 (0.48) KDM4EMEN1KMT2AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501833-B1 N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-11-02 EP disclosed
US-6900201-B2 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-05-31 US disclosed
US-20040010141-A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010141-A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP9, MMP8, MMP2 KDM4E 2200/4885POLB 1146/4885MEN1 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.